How to Become a STELFONTA® (tigilanol tiglate injection) SUPERSTAR: Part 2 of 4

1.0 CE Credit Hour / Veterinarians & Veterinary Technicians

Overview:

This is the second part of a four-part series. In this session we will delve into the four stages of treatment with STELFONTA®. The discussion will focus on a deep dive into Stage 1 (preparation with essential medications) and Stage 2 (STELFONTA® treatment), highlighting the unique considerations for small dogs with large tumors and appropriate dosing strategies. The role of the veterinary technician will be emphasized, along with essential tools for successful treatment. Real- life case examples, such as the cases of K2 and Nucky, will be shared to illustrate practical applications.

Learning Objectives:

  • Introduce the four stages of treatment with STELFONTA® (tigilanol tiglate injection).
  • Conduct a deep dive into Stage 1 (preparation with essential medications) and Stage 2
    (STELFONTA® treatment), focusing on small dogs with large tumors and appropriate dosing
    strategies.
  •  Identify essential tools required for effective STELFONTA® treatment.
  •  Understand the critical role of the veterinary technician in the treatment process.
  • Review real-life case studies (K2 and Nucky) to illustrate practical applications and effective
  • treatment strategies.

IMPORTANT SAFETY INFORMATION
Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

    Dr Sue Ettinger

    Dr Sue Ettinger

    DVM, Diplomate ACVIM (Oncology)

    This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.

    This activity is sponsored by Virbac.